SGLT-2 inhibitors could prevent autoimmune rheumatic disease

Sodium-glucose cotransporter-2 inhibitors may be effective in patients with autoimmune rheumatic disease.

In a study published in BMJ, investigators used the South Korea National Health Insurance Service database to examine the outcomes of more than 2 million patients with Type 2 diabetes who received either SGLT-2 inhibitors or sulfonylureas.

Compared with those who initiated sulfonylureas, the patients who initiated SGLT-2 inhibitors had a lower incidence rate of autoimmune rheumatic diseases.

The findings indicated the potential benefit of SGLT-2 inhibitors in this patient population. Nonetheless, clinicians should consider the risks associated with the drugs during the treatment decision-making process.

Read more: BMJ

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.